Related Experiment Video
Updated: May 4, 2026
Author Spotlight: A Novel Protocol for Intracameral Injections to Enhance Precision in Rodent Ophthalmology
Published on: May 31, 2024
Cefazolin Alone versus Vancomycin Plus Cefazolin for Intravenous Prophylaxis in Hip and Knee Arthroplasty: A
CaiMin Yang1, CaiLing Peng1, Jin Yan1
1The Third People's Hospital of Yibin, Yibin, Sichuan, China.
Insights
Dual antibiotic prophylaxis with vancomycin and cefazolin in total joint arthroplasty may lower periprosthetic joint infection (PJI) risk but does not reduce surgical site infections (SSI) and may increase superficial infections. A selective approach is recommended.
Area of Science:
- Orthopedic Surgery
- Infectious Diseases
- Pharmacology
Background:
- Periprosthetic joint infection (PJI) is a severe complication of total joint arthroplasty (TJA).
- Cefazolin is standard prophylaxis, but rising methicillin-resistant Staphylococcus aureus (MRSA) prompts dual prophylaxis with vancomycin and cefazolin.
- The efficacy and safety of dual prophylaxis are debated.
Purpose of the Study:
- To evaluate the efficacy and safety of dual prophylaxis (vancomycin and cefazolin) versus cefazolin alone for preventing infections in TJA.
- To compare rates of PJI, surgical site infection (SSI), and acute kidney injury (AKI).
Main Methods:
- Systematic review and meta-analysis of randomized controlled trials and observational studies.
- Searched PubMed, Web of Science, Embase, and Cochrane Library.
- Included studies comparing cefazolin alone vs. vancomycin plus cefazolin for intravenous prophylaxis in TJA patients.
Main Results:
- Eight studies with 1,041,058 patients were analyzed.
- Dual prophylaxis showed a higher risk of SSI (OR=1.39) but a lower risk of PJI (OR=0.64).
- No significant difference in AKI risk was found (OR=1.30), with substantial heterogeneity.
Conclusions:
- Routine dual prophylaxis does not decrease overall SSI rates and may increase superficial infections.
- Dual prophylaxis may reduce PJI risk without significantly increasing AKI.
- Findings support selective, risk-stratified prophylaxis over universal dual antibiotic therapy in TJA.
Background:
Periprosthetic joint infection (PJI) remains a devastating complication following total joint arthroplasty, leading to substantial morbidity and increased health care costs. Cefazolin is the standard agent for perioperative antibiotic prophylaxis. However, the rising prevalence of methicillin-resistant Staphylococcus aureus has prompted the use of dual prophylaxis with vancomycin and cefazolin. The efficacy and safety of this combined strategy remain controversial.
Methods:
A systematic review and meta-analysis were conducted following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines and registered on the international prospective register of systematic reviews (ID CRD420251077695). A comprehensive search of PubMed, Web of Science, Embase, and the Cochrane Library was performed. Randomized controlled trials and observational studies directly comparing cefazolin alone with combined vancomycin and cefazolin as intravenous prophylaxis in patients undergoing total joint arthroplasty were included. The primary outcome measures were PJI and surgical site infection (SSI), and secondary outcome measures were acute kidney injury (AKI). There were eight studies including 1,041,058 patients that met the inclusion criteria.
Results:
Dual prophylaxis was associated with a higher risk of SSI (odds ratio [OR] = 1.39; 95% confidence interval [CI] = 1.23 to 1.58), but a lower risk of PJI (OR = 0.64; 95% CI = 0.46 to 0.91). There was no significant difference in risk of AKI between regimens (OR = 1.30; 95% CI = 0.76 to 2.20), although substantial heterogeneity was observed among studies reporting renal outcomes.
Conclusions:
Routine addition of vancomycin to cefazolin does not reduce overall SSI rates and may increase superficial infections. However, it may decrease PJI risk without significantly increasing AKI. These findings support a selective, risk-stratified prophylactic strategy rather than universal dual antibiotic therapy in total joint arthroplasty.
Related Concept Videos
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
01:28Inhibitors of Bacterial DNA Synthesis